Nature Communications (journal)

August 25, 2022

Inflammatory driver of obesity

Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.

By Sarah E. Glass
The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.
July 20, 2022

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

By Leigh MacMillan
Eric Skaar, PhD, MPH, Hualiang Pi, PhD, and colleagues are studying a regulatory factor in the bacterium that causes the disease anthrax.
April 7, 2022

Study advances understanding of bacterial bioterrorism agent

Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon.

By Leigh MacMillan
(iStock)
January 20, 2022

New method enhances efforts to identify drug repurposing targets

Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.

By Paul Govern
November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

By Tom Wilemon
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
July 16, 2021

Study identifies monoclonal antibodies that may neutralize many norovirus variants

Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
By Bill Snyder
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
By Bill Snyder
September 17, 2020

New predictors of prostate cancer risk

An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk.
By Sarah E. Glass
August 20, 2020

‘Scavenger’ molecule may point to new atherosclerosis treatment

A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.
By Bill Snyder
July 23, 2020

Cellular antiviral defenses

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
By Leigh MacMillan
July 9, 2020

Recurrent UTIs linked to hidden reservoir

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.
By Sarah E. Glass
1 2 3 4 5